Welcome to our dedicated page for Becton Dickinson & news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & stock.
Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (Becton, Dickinson and Company) has joined the Race to Zero and the Business Ambition for 1.5°C, pledging to achieve net-zero emissions by 2050. This initiative aims to combat climate change, with commitments to reduce Scope 1 and 2 GHG emissions by 46% by 2030 and to be carbon neutral by 2040. The announcement will be celebrated on September 25, 2021, at the Global Citizen LIVE.
BD (Becton, Dickinson and Company) has been selected by Washington state to provide its BD Veritor™ Plus rapid antigen test for COVID-19 in K-12 schools. This easy-to-use test delivers results in just 15 minutes and will be available at no cost through a partnership with the Washington Department of Health. Schools can opt for a full-service testing program managed by Premier Medical Group, which will oversee testing protocols and result reporting. This service aims to keep schools open and safe while containing COVID-19 spread. The BD Veritor™ Plus system is authorized for emergency use, pending FDA clearance.
Vicarious Surgical and D8 Holdings Corp. have secured an additional $27 million in commitments for a private placement, raising total PIPE commitments to $142 million. The anticipated gross proceeds from their business combination amount to approximately $487 million, ensuring D8 meets the closing condition of having at least $125 million in available cash. Investors include Becton, Dickinson and Company (BD), major hospital groups, and notable figures like Bill Gates. Vicarious Surgical aims to enhance surgical outcomes using advanced robotics technology.
BD (Becton, Dickinson and Company) has received FDA Emergency Use Authorization for its BD Veritor™ At-Home COVID-19 Test. This is the first at-home rapid antigen test to use smartphone computer vision technology to digitally interpret results. The test requires no prescription and provides results in 15 minutes using a nasal swab and a mobile app. Initially targeting businesses and schools amid rising COVID-19 cases, the test aims to facilitate easier home testing, fulfilling government and business mandates for regular testing.
BD (Becton, Dickinson and Company) announced the launch of the BD COR™ System, a fully automated high-throughput diagnostic platform for infectious disease testing, specifically designed for core and centralized laboratories in the U.S. The system enhances laboratory efficiency by automating sample processing and diagnostics, eliminating extensive manual handling. Initially, it will support the BD Onclarity™ HPV Assay, capable of detecting multiple high-risk HPV types. This launch, following prior approval in Europe, marks a significant step in BD's molecular diagnostics strategy, enhancing capabilities for high-volume labs.
Becton, Dickinson and Company (NYSE: BDX) announced its tender offers for purchasing senior notes totaling $1,285,000,000. The offers include all of the Company’s 2.894% notes due 2022 and 3.300% notes due 2023, along with up to the maximum limits of several 2024 notes. Total Considerations for these notes are detailed, with early tender payments set at $30. The company expects to accept only those Maximum Tender Offer Notes validly tendered by the Early Tender Date of August 18, 2021. Investors are directed to the Offer to Purchase for complete terms.
Becton, Dickinson and Company (BD) announced early tender results for its cash tender offers on senior notes due 2022 and 2023, with a total maximum cap of $1.285 billion. As of August 18, 2021, $877.6 million of the 2.894% senior notes and $128.1 million of the 3.300% senior notes were tendered. The company plans to redeem any untendered 2.894% notes by September 13, 2021. The tender offers will lead to early settlements on August 20, 2021, with a prorated acceptance for certain notes exceeding their tender caps.
BD (Becton, Dickinson and Company) (NYSE: BDX) has announced the launch of the BD FACSymphony™ A1 Cell Analyzer, a benchtop system designed to enhance access to flow cytometry capabilities for laboratories of all sizes. This fluorescence-activated cell analyzer features advanced research capabilities and compact design, enabling efficient resource use and time-saving for researchers. The device supports various experiments from small particle studies to 16-color immunophenotyping, utilizing BD's industry-standard software for streamlined workflows.
BD (Becton, Dickinson and Company) has appointed Christopher DelOrefice as the new chief financial officer (CFO), effective Sept. 6, 2021, following Christopher Reidy's planned retirement. DelOrefice previously held key finance positions at Johnson & Johnson, contributing nearly two decades of experience in healthcare finance. His expertise will aid BD in executing its 2025 growth strategy and boosting shareholder value. DelOrefice's vast background, including roles in Investor Relations, positions him as a strong asset for BD's leadership team.
Becton, Dickinson and Company (NYSE: BDX) announced an amendment to its tender offers for certain Senior Notes due 2024. The maximum principal amount for its 3.734% Senior Notes has been increased from $300 million to $500 million, while the total maximum for all offered notes rises from $715 million to $1.285 billion. Other terms remain unchanged. The tender offers are outlined in the Offer to Purchase, dated August 5, 2021, which investors should carefully review for full details.